Share Price:


The Group was founded in 1978 in Amman, Jordan by the late Mr. Samih Darwazah, its former Chairman and Chief Executive Officer who retired in May 2014. At the time of its foundation, the Group was focussed on establishing its Branded business in the MENA region. In the early 1990s, the Group expanded outside the MENA region by establishing injectable pharmaceutical operations in Portugal and acquiring West-Ward Pharmaceuticals, a generics pharmaceutical business, in the United States. 

In 2005, the Group listed on the London Stock Exchange raising gross proceeds of US$124 million. A successful initial public offering enhanced the Group’s flexibility to grow the business both organically and through acquisitions. From 2005 onwards, the Group has expanded its presence in existing markets and entered new markets in the MENA region. It has also made significant acquisitions in Europe and the United States to strengthen its Injectables business.




 We were founded in Jordan, where we established ourselves as a leading supplier of branded generics and in-licensed products. 




We moved beyond the MENA and acquired land in Portugal for the construction of a sterile manufacturing plant for injectable pharmaceutical products.




We entered the US market through acquisition of West-Ward Pharmaceuticals in Eatontown, New Jersey.




We entered Tunisian market through acquisition of a minority stake in Industries Pharmaceutiques Ibn Al Baytar (IAB).




We started manufacturing at Jazeera Pharmaceutical Industries (JPI) in Saudi Arabia.




Our manufacturing plant in Portugal was approved by the US FDA. We started to manufacture injectable powder cephalosporins for sale in the MENA region and Portugal.




We listed on the London Stock Exchange.


Our Injectables business expanded into the lyophilised segment of the injectables market with the acquisition of a specialised manufacturing plant in Italy.




Our business in Saudi received US FDA approval.


We started manufacturing operations in Trust Pharma Algeria.




We expanded into the generic injectable oncology market through the acquisition of Ribosepharm GmbH and Thymoorgan in Germany.


We entered the Egyptian pharmaceutical market through the acquisition of Alkan Pharma and strengthened our market presence in Jordan through the acquisition of Arab Pharmaceutical Manufacturing Company (APM).




We acquired Al Dar Al Arabia in Algeria, for penicillin production.




We expanded the Injectables business through the acquisition of Baxter Healthcare Corporation’s multi-source injectables business (MSI).


We entered the Moroccan market through the acquisition of Société de Promotion Pharmaceutique du Maghreb S.A. (SPPM).


We strengthened our position in Sudan through acquisition of Elie Pharmaceuticals.




We acquired Egyptian Company for Pharmaceuticals and Chemical Industries (EPCI) to strengthen the Group’s position in the Egyptian market.




We acquired the assets of Bedford Laboratories (Bedford) and Ben Venue Laboratories, Inc. (Ben Venue).




We acquired EIMC United Pharmaceuticals (EUP), further strengthening our position in the Egyptian market.


We sold the Ben Venue site retaining the Quality Development Centre (QDC).



We acquired Roxane Laboratories (now West-Ward Columbus), transforming our position in the US market.